Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Hemab Therapeutics (Nasdaq: COAG) closed its upsized initial public offering on May 4, 2026, selling 19,262,500 shares at $18.00 per share, including 2,512,500 shares from full exercise of the underwriters' option.

Rhea-AI Summary

Hemab Therapeutics (Nasdaq: COAG) closed its upsized initial public offering on May 4, 2026, selling 19,262,500 shares at $18.00 per share, including 2,512,500 shares from full exercise of the underwriters' option. Gross proceeds were approximately $346.7 million.

The company’s common stock began trading on the Nasdaq Global Select Market on May 1, 2026 under ticker COAG. A registration statement was declared effective April 30, 2026.

Positive

• Gross proceeds of ~$346.7M from IPO
• Offering included 2,512,500 shares from full exercise of underwriters’ option
• Common stock began trading on Nasdaq Global Select under ticker COAG

Negative

• Net proceeds will be lower after underwriting discounts, commissions, and offering expenses
• Share issuance was primary: all shares sold by Hemab, diluting existing shareholders

Argus May 5 session

-1.34% close to close 461.17K volume Open Argus

Details

News Market Reaction – COAG

On May 5, the first trading day after this news, COAG closed 1.34% below the previous close.

Data tracked by StockTitan Argus for the May 5 session.

Key Figures

Shares offered: 19,262,500 shares Additional option shares: 2,512,500 shares IPO price: $18.00 per share +5 more

Shares offered

19,262,500 shares

Initial public offering size including exercised option

Additional option shares

2,512,500 shares

Underwriters’ option exercised in full

IPO price

$18.00 per share

Public offering price for COAG IPO

Gross proceeds

$346.7 million

Before underwriting discounts and expenses

Current price

$34.00

Price before this news release

52-week high

$36.61

Pre-news 52-week high for COAG

52-week low

$27.00

Pre-news 52-week low for COAG

Trading volume

4,089,622 shares

Today’s volume vs 20-day avg 4,099,705

Key Terms

initial public offering, underwriters, prospectus, registration statement, +2 more

6 terms

initial public offering financial

"announced the closing of its initial public offering of 19,262,500 shares"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

underwriters financial

"exercise in full by the underwriters of their option to purchase"

Underwriters are financial professionals or institutions that help companies raise money by selling new securities, such as stocks or bonds, to investors. They assess the risk and determine the price at which these securities should be sold, acting like a bridge between the company and the investors. Their role helps ensure that the company raises the needed funds while providing investors with options that reflect the level of risk involved.

prospectus regulatory

"The offering was made only by means of a prospectus."

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

registration statement regulatory

"A registration statement relating to the securities sold in the offering was filed"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

Securities and Exchange Commission (SEC) regulatory

"filed with the Securities and Exchange Commission (SEC) and was declared effective"

A U.S. federal agency that oversees the stock and securities markets, requiring public companies and brokers to register and share accurate financial information so investors can see the facts. It enforces rules, investigates fraud and can pause or change market activity; think of it as a referee whose decisions and investigations affect investor confidence, legal risk and the value of traded securities.

Nasdaq Global Select Market financial

"Hemab’s common stock began trading on the Nasdaq Global Select Market on Friday"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 04, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced the closing of its initial public offering of 19,262,500 shares of its common stock at a public offering price of $18.00 per share, including 2,512,500 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares of common stock were sold by Hemab. Hemab’s common stock began trading on the Nasdaq Global Select Market on Friday, May 1, 2026 under the ticker symbol “COAG.” The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Hemab, were approximately $346.7 million.

Goldman Sachs & Co. LLC, Jefferies and Evercore ISI acted as joint book-running managers for the offering. Wedbush PacGrow acted as lead manager for the offering.

A registration statement relating to the securities sold in the offering was filed with the Securities and Exchange Commission (SEC) and was declared effective on April 30, 2026. Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov. The offering was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526, or by email at prospectus-ny@ny.email.gs.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Hemab Therapeutics

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab’s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, and HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease.

Media:
Deerfield
Peg Rusconi
peg.rusconi@deerfieldgroup.com

Investors:
Hemab Therapeutics
Mads Behrndt
investors@hemab.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Hemab Therapeutics (COAG) sell in its May 2026 IPO?

Hemab sold 19,262,500 shares in the IPO, including 2,512,500 additional shares from the underwriters' option. According to the company, all shares were sold by Hemab at a public offering price of $18.00 per share.

What were the gross proceeds for Hemab Therapeutics (COAG) from the IPO on May 4, 2026?

Gross proceeds were approximately $346.7 million before fees and expenses. According to the company, this figure is prior to deducting underwriting discounts, commissions and other offering expenses payable by Hemab.

When did Hemab Therapeutics (COAG) start trading on Nasdaq and under what ticker?

Hemab's common stock began trading on the Nasdaq Global Select Market on May 1, 2026 under the ticker COAG. According to the company, the listing followed an effective SEC registration declared on April 30, 2026.

Which banks managed Hemab Therapeutics' (COAG) May 2026 IPO?

Goldman Sachs, Jefferies, and Evercore ISI acted as joint book-running managers, with Wedbush PacGrow as lead manager. According to the company, these firms handled syndication and distribution for the offering.

Will Hemab Therapeutics (COAG) receive the full $346.7M in cash after the IPO?

No. The company reported $346.7 million as gross proceeds; net proceeds will be lower after underwriting discounts, commissions and offering expenses. According to the company, those costs are payable by Hemab and will reduce cash received.